Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 168

1.

MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with 99mTc(I) Tricarbonyl Complex.

Ku A, Chan C, Aghevlian S, Cai Z, Cescon D, Bratman SV, Ailles L, Hedley DW, Reilly RM.

Mol Pharm. 2019 Aug 5;16(8):3559-3568. doi: 10.1021/acs.molpharmaceut.9b00422. Epub 2019 Jul 11.

PMID:
31242384
2.

Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

Michelis FV, Hedley DW, Malhotra S, Chow S, Loach D, Gupta V, Kim DD, Kuruvilla J, Lipton JH, Viswabandya A, Messner HA.

Biol Blood Marrow Transplant. 2019 Jun;25(6):1158-1163. doi: 10.1016/j.bbmt.2019.01.014. Epub 2019 Jan 14.

PMID:
30654137
3.

Radioimmunotherapy of PANC-1 Human Pancreatic Cancer Xenografts in NRG Mice with Panitumumab Modified with Metal-Chelating Polymers Complexed to 177Lu.

Aghevlian S, Cai Z, Lu Y, Hedley DW, Winnik MA, Reilly RM.

Mol Pharm. 2019 Feb 4;16(2):768-778. doi: 10.1021/acs.molpharmaceut.8b01040. Epub 2019 Jan 10.

PMID:
30589553
4.

Comparison of Practice Guidelines, BRCAPRO, and Genetic Counselor Estimates to Identify Germline BRCA1 and BRCA2 Mutations in Pancreatic Cancer.

Grant RC, Holter S, Borgida A, Dhani NC, Hedley DW, Knox JJ, Akbari MR, Zogopoulos G, Gallinger S.

J Genet Couns. 2018 Aug;27(4):988-995. doi: 10.1007/s10897-018-0212-1. Epub 2018 Feb 13.

PMID:
29441441
5.

Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.

Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.

Mol Pharm. 2018 Mar 5;15(3):1150-1159. doi: 10.1021/acs.molpharmaceut.7b01000. Epub 2018 Jan 30.

PMID:
29314858
6.

Impact of tissue transport on PET hypoxia quantification in pancreatic tumours.

Taylor E, Gottwald J, Yeung I, Keller H, Milosevic M, Dhani NC, Siddiqui I, Hedley DW, Jaffray DA.

EJNMMI Res. 2017 Dec 22;7(1):101. doi: 10.1186/s13550-017-0347-3.

7.

Imaging Mass Cytometry.

Chang Q, Ornatsky OI, Siddiqui I, Loboda A, Baranov VI, Hedley DW.

Cytometry A. 2017 Feb;91(2):160-169. doi: 10.1002/cyto.a.23053. Epub 2017 Feb 3.

8.

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.

Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.

PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.

9.

Activity of the novel polo-like kinase 4 inhibitor CFI-400945 in pancreatic cancer patient-derived xenografts.

Lohse I, Mason J, Cao PM, Pintilie M, Bray M, Hedley DW.

Oncotarget. 2017 Jan 10;8(2):3064-3071. doi: 10.18632/oncotarget.13619.

10.

Cancer initiating-cells are enriched in the CA9 positive fraction of primary cervix cancer xenografts.

Marie-Egyptienne DT, Chaudary N, Kalliomäki T, Hedley DW, Hill RP.

Oncotarget. 2017 Jan 3;8(1):1392-1404. doi: 10.18632/oncotarget.13625.

11.

Biodistribution of cisplatin revealed by imaging mass cytometry identifies extensive collagen binding in tumor and normal tissues.

Chang Q, Ornatsky OI, Siddiqui I, Straus R, Baranov VI, Hedley DW.

Sci Rep. 2016 Nov 4;6:36641. doi: 10.1038/srep36641.

12.

Quantifying hypoxia in human cancers using static PET imaging.

Taylor E, Yeung I, Keller H, Wouters BG, Milosevic M, Hedley DW, Jaffray DA.

Phys Med Biol. 2016 Nov 21;61(22):7957-7974. Epub 2016 Oct 25.

PMID:
27779123
13.

Porphysome nanoparticles for enhanced photothermal therapy in a patient-derived orthotopic pancreas xenograft cancer model: a pilot study.

MacLaughlin CM, Ding L, Jin C, Cao P, Siddiqui I, Hwang DM, Chen J, Wilson BC, Zheng G, Hedley DW.

J Biomed Opt. 2016 Aug 1;21(8):84002. doi: 10.1117/1.JBO.21.8.084002.

14.

Novel regulatory role of neuropilin-1 in endothelial-to-mesenchymal transition and fibrosis in pancreatic ductal adenocarcinoma.

Matkar PN, Singh KK, Rudenko D, Kim YJ, Kuliszewski MA, Prud'homme GJ, Hedley DW, Leong-Poi H.

Oncotarget. 2016 Oct 25;7(43):69489-69506. doi: 10.18632/oncotarget.11060.

15.

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience.

Chllamma MK, Cook N, Dhani NC, Giby K, Dodd A, Wang L, Hedley DW, Moore MJ, Knox JJ.

Br J Cancer. 2016 Sep 6;115(6):649-54. doi: 10.1038/bjc.2016.222. Epub 2016 Jul 28.

16.

A phase I trial of the aurora kinase inhibitor, ENMD-2076, in patients with relapsed or refractory acute myeloid leukemia or chronic myelomonocytic leukemia.

Yee KW, Chen HW, Hedley DW, Chow S, Brandwein J, Schuh AC, Schimmer AD, Gupta V, Sanfelice D, Johnson T, Le LW, Arnott J, Bray MR, Sidor C, Minden MD.

Invest New Drugs. 2016 Oct;34(5):614-24. doi: 10.1007/s10637-016-0375-2. Epub 2016 Jul 12.

PMID:
27406088
17.

Targeting hypoxic microenvironment of pancreatic xenografts with the hypoxia-activated prodrug TH-302.

Lohse I, Rasowski J, Cao P, Pintilie M, Do T, Tsao MS, Hill RP, Hedley DW.

Oncotarget. 2016 Jun 7;7(23):33571-80. doi: 10.18632/oncotarget.9654.

18.

Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake.

Metran-Nascente C, Yeung I, Vines DC, Metser U, Dhani NC, Green D, Milosevic M, Jaffray D, Hedley DW.

J Nucl Med. 2016 Mar;57(3):361-6. doi: 10.2967/jnumed.115.167650. Epub 2016 Jan 14.

19.

Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole.

Dhani NC, Serra S, Pintilie M, Schwock J, Xu J, Gallinger S, Hill RP, Hedley DW.

Br J Cancer. 2015 Sep 15;113(6):864-71. doi: 10.1038/bjc.2015.284. Epub 2015 Sep 1.

20.

BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.

Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.

Br J Cancer. 2015 Jul 28;113(3):425-32. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.

21.

Chromosomal instability as a prognostic marker in cervical cancer.

How C, Bruce J, So J, Pintilie M, Haibe-Kains B, Hui A, Clarke BA, Hedley DW, Hill RP, Milosevic M, Fyles A, Liu FF.

BMC Cancer. 2015 May 6;15:361. doi: 10.1186/s12885-015-1372-0.

22.

Developing a prognostic micro-RNA signature for human cervical carcinoma.

How C, Pintilie M, Bruce JP, Hui AB, Clarke BA, Wong P, Yin S, Yan R, Waggott D, Boutros PC, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF.

PLoS One. 2015 Apr 16;10(4):e0123946. doi: 10.1371/journal.pone.0123946. eCollection 2015.

23.

MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.

Boyle AJ, Cao PJ, Hedley DW, Sidhu SS, Winnik MA, Reilly RM.

Nucl Med Biol. 2015 Feb;42(2):71-7. doi: 10.1016/j.nucmedbio.2014.10.009. Epub 2014 Oct 22.

PMID:
25456837
24.

Single-cell measurement of the uptake, intratumoral distribution and cell cycle effects of cisplatin using mass cytometry.

Chang Q, Ornatsky OI, Koch CJ, Chaudary N, Marie-Egyptienne DT, Hill RP, Tanner SD, Hedley DW.

Int J Cancer. 2015 Mar 1;136(5):1202-9. doi: 10.1002/ijc.29074. Epub 2014 Jul 16.

25.

Assessment of hypoxia in the stroma of patient-derived pancreatic tumor xenografts.

Lohse I, Lourenco C, Ibrahimov E, Pintilie M, Tsao MS, Hedley DW.

Cancers (Basel). 2014 Feb 26;6(1):459-71. doi: 10.3390/cancers6010459.

26.

High tumor interstitial fluid pressure identifies cervical cancer patients with improved survival from radiotherapy plus cisplatin versus radiotherapy alone.

Milosevic MF, Pintilie M, Hedley DW, Bristow RG, Wouters BG, Oza AM, Laframboise S, Hill RP, Fyles AW.

Int J Cancer. 2014 Oct 1;135(7):1692-9. doi: 10.1002/ijc.28403. Epub 2014 Apr 25.

27.

MicroRNA-196b regulates the homeobox B7-vascular endothelial growth factor axis in cervical cancer.

How C, Hui AB, Alajez NM, Shi W, Boutros PC, Clarke BA, Yan R, Pintilie M, Fyles A, Hedley DW, Hill RP, Milosevic M, Liu FF.

PLoS One. 2013 Jul 4;8(7):e67846. doi: 10.1371/journal.pone.0067846. Print 2013.

28.

Tumor-stroma interaction in orthotopic primary pancreatic cancer xenografts during hedgehog pathway inhibition.

Chang Q, Foltz WD, Chaudary N, Hill RP, Hedley DW.

Int J Cancer. 2013 Jul;133(1):225-34. doi: 10.1002/ijc.28006. Epub 2013 Feb 5.

29.

Sequence dependence of MEK inhibitor AZD6244 combined with gemcitabine for the treatment of biliary cancer.

Xu J, Knox JJ, Ibrahimov E, Chen E, Serra S, Tsao M, Cao P, Vines D, Green DE, Metran-Nascente C, McNamara MG, Hedley DW.

Clin Cancer Res. 2013 Jan 1;19(1):118-27. doi: 10.1158/1078-0432.CCR-12-2557. Epub 2012 Oct 22.

30.

Glycogen synthase kinase-3 inhibition sensitizes pancreatic cancer cells to TRAIL-induced apoptosis.

Mamaghani S, Simpson CD, Cao PM, Cheung M, Chow S, Bandarchi B, Schimmer AD, Hedley DW.

PLoS One. 2012;7(7):e41102. doi: 10.1371/journal.pone.0041102. Epub 2012 Jul 19.

31.

Orthotopic xenograft model of cervical cancer for studying microenvironmental effects on metastasis formation and response to drug treatment.

Chaudary N, Hedley DW, Hill RP.

Curr Protoc Pharmacol. 2011 Jun;Chapter 14:Unit 14.19. doi: 10.1002/0471141755.ph1419s53.

PMID:
21935900
32.

Cytometry of intracellular signaling: from laboratory bench to clinical application.

Hedley DW, Chow S, Shankey TV.

Methods Cell Biol. 2011;103:203-20. doi: 10.1016/B978-0-12-385493-3.00009-7. Review.

PMID:
21722805
33.

Tenofovir selectively regulates production of inflammatory cytokines and shifts the IL-12/IL-10 balance in human primary cells.

Melchjorsen J, Risør MW, Søgaard OS, O'Loughlin KL, Chow S, Paludan SR, Ellermann-Eriksen S, Hedley DW, Minderman H, Østergaard L, Tolstrup M.

J Acquir Immune Defic Syndr. 2011 Aug 1;57(4):265-75. doi: 10.1097/QAI.0b013e3182185276.

PMID:
21471820
34.

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

Brandwein JM, Hedley DW, Chow S, Schimmer AD, Yee KW, Schuh AC, Gupta V, Xu W, Kamel-Reid S, Minden MD.

Leukemia. 2011 Jun;25(6):945-52. doi: 10.1038/leu.2011.34. Epub 2011 Mar 15.

PMID:
21403650
35.

Gemcitabine-induced acute myositis in a patient with duodenal cancer.

Wong KM, Khanna M, Wu RC, Hedley DW.

Clin Oncol (R Coll Radiol). 2011 Sep;23(7):492-3. doi: 10.1016/j.clon.2011.02.007. Epub 2011 Mar 3. No abstract available.

PMID:
21376549
36.

Hypoxia predicts aggressive growth and spontaneous metastasis formation from orthotopically grown primary xenografts of human pancreatic cancer.

Chang Q, Jurisica I, Do T, Hedley DW.

Cancer Res. 2011 Apr 15;71(8):3110-20. doi: 10.1158/0008-5472.CAN-10-4049. Epub 2011 Feb 22.

37.

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Chang Q, Chapman MS, Miner JN, Hedley DW.

BMC Cancer. 2010 Sep 28;10:515. doi: 10.1186/1471-2407-10-515.

38.

A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.

You B, Brade A, Magalhaes JM, Siu LL, Oza A, Lovell S, Wang L, Hedley DW, Nicacio LV, Chen EX.

Invest New Drugs. 2011 Oct;29(5):996-1003. doi: 10.1007/s10637-010-9444-0. Epub 2010 May 8.

PMID:
20454832
39.

SNAI1 expression and the mesenchymal phenotype: an immunohistochemical study performed on 46 cases of oral squamous cell carcinoma.

Schwock J, Bradley G, Ho JC, Perez-Ordonez B, Hedley DW, Irish JC, Geddie WR.

BMC Clin Pathol. 2010 Feb 5;10:1. doi: 10.1186/1472-6890-10-1.

40.

Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.

Chang Q, Chen E, Hedley DW.

Cancer Biol Ther. 2009 Oct;8(20):1893-901. Epub 2009 Oct 6.

PMID:
20009539
41.

Targeting focal adhesion kinase signaling in tumor growth and metastasis.

Schwock J, Dhani N, Hedley DW.

Expert Opin Ther Targets. 2010 Jan;14(1):77-94. doi: 10.1517/14728220903460340. Review.

PMID:
20001212
42.

Potential use of cetrimonium bromide as an apoptosis-promoting anticancer agent for head and neck cancer.

Ito E, Yip KW, Katz D, Fonseca SB, Hedley DW, Chow S, Xu GW, Wood TE, Bastianutto C, Schimmer AD, Kelley SO, Liu FF.

Mol Pharmacol. 2009 Nov;76(5):969-83. doi: 10.1124/mol.109.055277. Epub 2009 Aug 4.

PMID:
19654225
43.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3.

44.

Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts.

Schwock J, Dhani N, Cao MP, Zheng J, Clarkson R, Radulovich N, Navab R, Horn LC, Hedley DW.

Cancer Res. 2009 Jun 1;69(11):4750-9. doi: 10.1158/0008-5472.CAN-09-0454. Epub 2009 May 19.

45.
46.

Activity of a novel, dual PI3-kinase/mTor inhibitor NVP-BEZ235 against primary human pancreatic cancers grown as orthotopic xenografts.

Cao P, Maira SM, García-Echeverría C, Hedley DW.

Br J Cancer. 2009 Apr 21;100(8):1267-76. doi: 10.1038/sj.bjc.6604995. Epub 2009 Mar 24.

47.

Cancer stem cells, hypoxia and metastasis.

Hill RP, Marie-Egyptienne DT, Hedley DW.

Semin Radiat Oncol. 2009 Apr;19(2):106-11. doi: 10.1016/j.semradonc.2008.12.002. Review.

PMID:
19249648
48.

Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models.

Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, Hill RP, Hedley DW.

Int J Cancer. 2009 Jan 15;124(2):280-6. doi: 10.1002/ijc.23912.

49.

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer.

Chang Q, Jorgensen C, Pawson T, Hedley DW.

Br J Cancer. 2008 Oct 7;99(7):1074-82. doi: 10.1038/sj.bjc.6604676. Epub 2008 Sep 16.

50.

Cyproheptadine displays preclinical activity in myeloma and leukemia.

Mao X, Liang SB, Hurren R, Gronda M, Chow S, Xu GW, Wang X, Beheshti Zavareh R, Jamal N, Messner H, Hedley DW, Datti A, Wrana JL, Zhu Y, Shi CX, Lee K, Tiedemann R, Trudel S, Stewart AK, Schimmer AD.

Blood. 2008 Aug 1;112(3):760-9. doi: 10.1182/blood-2008-02-142687. Epub 2008 May 23.

Supplemental Content

Loading ...
Support Center